September 18, 2020 — Elizabeth Wright
President Trump signed an Executive Order (EO) that implemented the “most favored nation” policy to lower drug costs that has been a topic of controversy since July 24, 2020.
September 18, 2020 — Elizabeth Wright 1600484735
September 11, 2020 — Elizabeth Wright
President Trump's health insurance transparency rule may not accomplish what is intended.
September 11, 2020 — Elizabeth Wright 1599839109
CCAGW has long called for significant reforms to the 340B drug discount program and asks that Congress focus on reforming the program instead of signing a letter.
September 4, 2020 — Elizabeth Wright
On August 31, the California state legislature passed, SB 852, The California Affordable Drug Manufacturing Act of 2020, which would allow the state to partner with drug manufacturers to produce their own line of pharmaceuticals.
September 4, 2020 — Elizabeth Wright 1599225578
August 28, 2020 — Elizabeth Wright
Is Montgomery County, Maryland and its approach to reopening public schools emblematic of many other school districts across the country?
August 28, 2020 — Elizabeth Wright 1598647441
August 21, 2020 — Elizabeth Wright
In March 2020, the Supreme Court of the United States (SCOTUS) agreed it would take up the case Texas v United States and determine the constitutionality of the Patient Protection and Affordable Care Act (ACA), or Obamacare.
August 21, 2020 — Elizabeth Wright 1598032260
August 19, 2020 — Elizabeth Wright
HHS sends a clear message to AGs regarding march-in rights.
August 19, 2020 — Elizabeth Wright 1597864551
August 11, 2020 — Elizabeth Wright
President Trump has been talking about signing a Buy American Executive Order (EO) since March, 2020 and did so on August 6.
August 11, 2020 — Elizabeth Wright 1597181946
Dear President Trump:
On behalf of the undersigned federal and state-based organizations, we write to express our grave concerns with the “most favored nation” (MFN) executive order to impose foreign price controls on American medicines.
This proposal will impose an “International Pricing Index” on drugs in Medicare Part B, tying the U.S. prices for these medicines to the prices in foreign countries, most of which have government-set prices established in socialized medicine systems.
CAGW Comments to the NAIC Concerning Pharmacy Benefit Managers
CAGW writes comments to the National Association of Insurance Commissioners regarding draft model legislation concerning pharmacy benefit managers.